Rapamycin nanoparticles mitigate anti-AAV antibody formation in a mouse model of ornithine transcarbamylase deficiency.
- DOI
- 10.1016/j.omta.2026.201793
- Published
- 2026 Sep 10
- Container
- Molecular therapy. Advances
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.omta.2026.201793,
title = {Rapamycin nanoparticles mitigate anti-AAV antibody formation in a mouse model of ornithine transcarbamylase deficiency.},
author = {Vicidomini A and Boisgerault F and Romano G and Guarnaccia C and Vidal P and Collaud F and Soria LR and de Sabbata G and Tedesco N and Lisjak M and Saxena H and Camparini L and Iaconcig A and Moretti L and Skoko N and Ilyinskii P and Brunetti-Pierri N and Bortolussi G and Ronzitti G and Kishimoto TK and Muro AF},
year = {2026},
journal = {Molecular therapy. Advances},
doi = {10.1016/j.omta.2026.201793},
url = {https://doi.org/10.1016/j.omta.2026.201793}
}RIS
TY - JOUR TI - Rapamycin nanoparticles mitigate anti-AAV antibody formation in a mouse model of ornithine transcarbamylase deficiency. AU - Vicidomini A AU - Boisgerault F AU - Romano G AU - Guarnaccia C AU - Vidal P AU - Collaud F AU - Soria LR AU - de Sabbata G AU - Tedesco N AU - Lisjak M AU - Saxena H AU - Camparini L AU - Iaconcig A AU - Moretti L AU - Skoko N AU - Ilyinskii P AU - Brunetti-Pierri N AU - Bortolussi G AU - Ronzitti G AU - Kishimoto TK AU - Muro AF PY - 2026 JO - Molecular therapy. Advances DO - 10.1016/j.omta.2026.201793 UR - https://doi.org/10.1016/j.omta.2026.201793 ER -
APA
A, V., F, B., G, R., C, G., P, V., F, C., LR, S., G, D. S., N, T., M, L., H, S., L, C., A, I., L, M., N, S., P, I., N, B., G, B., G, R., TK, K., & AF, M. (2026). Rapamycin nanoparticles mitigate anti-AAV antibody formation in a mouse model of ornithine transcarbamylase deficiency.. Molecular therapy. Advances. https://doi.org/10.1016/j.omta.2026.201793
Source records
- pubmed · retrieved 2026-09-26T02:15:52.710Z